SCHEMBL3725911

SCHEMBL3725911

CCOC(=O)c1nnc(-c2ncccn2)s1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.45
P2RY1 P47900 1/20 0.43
CDC7 O00311 4/20 0.43
DBF4 Q9UBU7 4/20 0.43
HPGD P15428 3/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
HSD17B10 Q99714 1/20 0.42
AKT1 P31749 1/20 0.40
IRS1 P35568 1/20 0.40
GAB1 Q13480 1/20 0.40
BRD4 O60885 1/20 0.40
OGA O60502 1/20 0.39
HTT P42858 1/20 0.39
CYP1A2 P05177 2/20 0.39
TRPM8 Q7Z2W7 1/20 0.39
TERT O14746 1/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30839468 0.83 LMNA (0.63) LMNAP2RY1HPGDKDM4EALDH1A1
SCHEMBL3717062 0.83 LMNA (0.63) LMNAP2RY1HPGDKDM4EALDH1A1
SCHEMBL22617519 0.82 P2RY1 (0.44) LMNAP2RY1CDC7DBF4KDM4E
SCHEMBL22617535 0.80 P2RY1 (0.43) LMNAP2RY1CDC7DBF4HPGD
SCHEMBL2179717 0.79 TRPM8 (0.58) LMNACDC7DBF4HPGDKDM4E
SCHEMBL17212202 0.78 CDC7 (0.62) CDC7DBF4HPGDKDM4EALDH1A1
SCHEMBL22617530 0.77 CDC7 (0.63) LMNACDC7DBF4HPGDKDM4E
SCHEMBL12571310 0.77 TERT (0.43) LMNAP2RY1KDM4EALDH1A1TERT
SCHEMBL22619842 0.76 CDC7 (0.47) LMNAP2RY1CDC7DBF4AKT1
SCHEMBL1638585 0.76 CDC7 (0.56) CDC7DBF4KDM4EALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3388428-B1 FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR SUZHOU SINOVENT PHARMACEUTICALS COMPANY (CN) 2021-08-04 EP disclosed
US-10821104-B2 Five-membered heterocyclic amides WNT pathway inhibitor Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) 2020-11-03 US disclosed
EP-3216798-A2 KETOLIDE COMPOUNDS Wockhardt Limited (IN) 2017-09-13 EP disclosed
EP-2673285-B1 KETOLIDE COMPOUNDS WOCKHARDT LTD (IN) 2017-07-19 EP disclosed
US-20160083412-A1 KETOLIDE COMPOUNDS WOCKHARDT LIMITED (IN) 2016-03-24 US disclosed
US-20160083412-A1 KETOLIDE COMPOUNDS WOCKHARDT LIMITED (IN) 2016-03-24 US disclosed
US-9175031-B2 Ketolide compounds WOCKHARDT LIMITED (IN) 2015-11-03 US disclosed
US-9175031-B2 Ketolide compounds WOCKHARDT LIMITED (IN) 2015-11-03 US disclosed
EP-2435460-B1 KETOLIDE COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY WOCKHARDT LTD (IN) 2015-01-07 EP disclosed
CN-102459296-B ketolide compounds having antimicrobial activity WOCKHARDT RESEARCH CENTRE (IN) 2014-10-29 CN disclosed
US-8541420-B2 Ketolide compounds having antimicrobial activity WOCKHARDT LTD. (IN) 2013-09-24 US disclosed
WO-2012076989-A1 KETOLIDE COMPOUNDS WOCKHARDT LIMITED (IN) 2012-06-14 WO disclosed
US-20120142710-A1 Ketolide Compounds Having Antimicrobial Activity WOCKHARDT LIMITED (IN) 2012-06-07 US disclosed
WO-2010136971-A1 KETOLIDE COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY WOCKHARDT RESEARCH CENTRE (IN) 2010-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10821104-B2 Five-membered heterocyclic amides WNT pathway inhibitor WNT1, WNT3, WNT3A LMNA 3903/4885P2RY1 3852/4885CDC7 258/4885
US-20120142710-A1 Ketolide Compounds Having Antimicrobial Activity CYP51A1, AKR1A1, AKR1C1 LMNA 3964/4885P2RY1 3123/4885CDC7 2069/4885
US-20160083412-A1 KETOLIDE COMPOUNDS AKR1C3, AKR1D1, AKR1C1 LMNA 4283/4885P2RY1 800/4885CDC7 2205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.